Description
Indication & Scope
MaiLiSheng® Albipagrastim Alfa for Injection reduces the incidence of chemotherapy-induced neutropenia in adult patients with non-myeloid malignant tumors receiving myelosuppressive chemotherapy.
- Mechanism: A long-acting recombinant human granulocyte colony-stimulating factor (G-CSF). It binds to receptors on bone marrow granulocyte progenitor cells, stimulates proliferation and differentiation of neutrophils, and accelerates neutrophil recovery after chemotherapy suppression.
- Drug class: Recombinant hematopoietic growth factor, injectable prescription biologic drug.
- Clinical use: Prophylactic treatment for chemotherapy-related neutropenia to lower febrile neutropenia risk and chemotherapy delay rates.
| Generic Name | Albipagrastim Alfa for Injection |
| Brand Name | MaiLiSheng |
| Ingredient | Albipagrastim Alfa |
| Dosage Form | Injection |
| Package | 20mg*1 vial/box |
| Conditions Treated | Chemotherapy-induced neutropenia in patients with non-myeloid solid malignant tumors |
| Taboos | Severe hypersensitivity to alipagrastim alfa, E. coli-derived protein excipients; patients with congenital severe neutropenia |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store sealed at 2°C to 8°C, protected from light, do not freeze |
| Manufacturer | QiLu Pharmaceutical, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20250021 |
| Approval Date | May 27, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Single fixed weight-based subcutaneous injection once per chemotherapy cycle.
Time: Administered 24 hours after the completion of myelosuppressive chemotherapy.
Instructions for use: Reconstitute powder with sterile water for injection; subcutaneous injection is preferred; intravenous slow drip is acceptable for hospitalized patients. Do not administer within 24 hours before chemotherapy.
Interaction: Concurrent use with chemotherapy drugs directly counteracts efficacy and is forbidden; no major interactions with supportive anti-emetic or anti-tumor auxiliary drugs.
Side effects: Mild bone pain, myalgia, injection site erythema, fatigue; rare splenomegaly and leukocytosis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the main clinical indication of Albipagrastim Alfa for Injection?
It is used to reduce the incidence of chemotherapy-induced neutropenia in adult patients with non-myeloid malignant tumors.
What drug class does Albipagrastim Alfa for Injection belong to?
It is a long-acting recombinant human granulocyte colony-stimulating factor biologic drug.
How does Albipagrastim Alfa for Injection work in the human body?
It stimulates the proliferation and differentiation of bone marrow neutrophils and accelerates immune cell recovery after chemotherapy suppression.
When is the correct administration time for using Albipagrastim Alfa for Injection?
It should be injected 24 hours after the completion of chemotherapy and never before chemotherapy.
MaiLiSheng® | Albipagrastim Alfa for Injection | Malignant Tumor | DengYueRX
INN: Albipagrastim Alfa for Injection
Indications: Non myeloid malignant tumor
Dosage Form: Injection
Strength: 20mg/vial
